Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1995-8-7
|
| pubmed:abstractText |
Mice, homozygous for the mutation severe combined immunodeficiency (scid) and also segregating for the mutation hypogonadal (hpg), were tested for their potential use as an in vivo model system for studying the growth of human prostate cancer and benign hyperplastic prostate tissue grafts. Fresh human prostate cancer or benign hyperplastic prostate tissue was implanted subcutaneously into androgen-replete C.B. 17 scid/scid males, and into androgen-deficient hpg/hpg scid/scid or androgen-replete +/? scid scid males. The tissue grafts grew in both androgen-replete and androgen-deficient host mice. When dihydrotestosterone (DHT) was administered at tissue grafting, both the incidence and size of the tissue grafts increased. Histology of tissue from tumors in the androgen-deficient hpg/hpg scid/scid host showed either undifferentiated tumors or adenocarcinomas with few glandular structures. These data suggest the androgen deficient environment selected for growth of androgen-independent tumor tissue. Finally, when interleukin-2 (IL-2)-activated tumor-infiltrating lymphocytes were injected into scid/scid hosts, the cells were found to survive and could be identified in the spleen of the recipient mice. These results indicate that growth of human prostate tissues and IL-2-activated lymphocytes in scid/scid mice is a viable model system for in vivo studies of prostatic disease.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0270-4137
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
27
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
32-41
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:7541529-Adenocarcinoma,
pubmed-meshheading:7541529-Animals,
pubmed-meshheading:7541529-Cell Survival,
pubmed-meshheading:7541529-Disease Models, Animal,
pubmed-meshheading:7541529-Flow Cytometry,
pubmed-meshheading:7541529-Humans,
pubmed-meshheading:7541529-Interleukin-2,
pubmed-meshheading:7541529-Lymphocyte Subsets,
pubmed-meshheading:7541529-Lymphocytes, Tumor-Infiltrating,
pubmed-meshheading:7541529-Male,
pubmed-meshheading:7541529-Mice,
pubmed-meshheading:7541529-Mice, SCID,
pubmed-meshheading:7541529-Neoplasm Transplantation,
pubmed-meshheading:7541529-Neoplasms, Hormone-Dependent,
pubmed-meshheading:7541529-Prostate-Specific Antigen,
pubmed-meshheading:7541529-Prostatic Hyperplasia,
pubmed-meshheading:7541529-Prostatic Neoplasms,
pubmed-meshheading:7541529-Testosterone,
pubmed-meshheading:7541529-Tumor Cells, Cultured
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Survival of human prostate carcinoma, benign hyperplastic prostate tissues, and IL-2-activated lymphocytes in scid mice.
|
| pubmed:affiliation |
Department of Urology, University of Iowa, Iowa City 52242-1089, USA.
|
| pubmed:publicationType |
Journal Article
|